Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.

Inclusion Criteria: * Men and women ≥ 18 years old * Diagnosed with Relapsing Remitting Multiple Sclerosis. Patients must be stable defined as free from relapsing episode for at least 6 months prior to Baseline * Patients must be treated with Interferon beta for at least one year * Patients must have an Expanded Disability Status Scale (EDSS) score ≤ 5 * Female patients must be post-menopausal (defined as at least 12 months post cessation of menses), surgically sterile or, if of childbearing potential, using a reliable method of contraception for at least 3 months prior to Baseline and during the study. In addition, female patients must not be lactating * Patients must be able to understand and comply with study requirements * Patients must provide a written, dated and signed informed consent prior to any study procedure Exclusion Criteria: * Any relapse of multiple sclerosis within the past 6 months prior to Screening Visit/Visit -1 * Any change in Interferon treatment within the past year prior to Screening Visit (Visit -1) * Expected use of another disease modifying therapy from Screening Visit/Visit -1 to Visit 3/Final Visit * Patients unable to undergo MRI scan * Current or expected use of a medication that could interfere with olesoxime pharmacology (e.g. tamoxifen) * Current or expected use of lipid lowering agents (ezetimibe, bile salt chelators, fibrates, phytosterols) other than statins * Known hypersensitivity to olesoxime or any of its components * History of alcohol or drug abuse within the last 6 months, or addiction within the last 2 years prior to Baseline Visit * Positive urinary pregnancy test at Baseline Visit * History of hepatitis B/C or HIV positive serology * Hepatic impairment (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\> 3 × ULN) at Baseline Visit * History of renal impairment defined by a serum creatinine value \> 176 μmol/L (2.0 mg/dL) at Baseline Visit * Abnormal and clinically significant ECG at Screening Visit/Visit -1 as assessed by a cardiologist * Current or expected use of oral or intramuscular corticosteroids within 3 months prior to the Screening Visit. Only stable dose regimens of inhaled and topical corticosteroids are allowed during the study * History of any clinically relevant gastrointestinal (GI), respiratory, psychiatric, neurological, kidney, liver, cardiac diseases, bleeding disorder, other disease/condition or abnormal physical finding which may interfere with the study objectives or put the patient's safety at risk, as judged by the Investigator * Patients with an active chronic disease (or stable but treated with immune therapy) of the immune system other than Multiple Sclerosis (MS) * History of malignancy of any organ, treated or non-treated within the past 5 years * Current participation or participation within 30 days prior to study entry, in another investigational drug or device study, or previous enrolment in the present study * Any direct involvement with the study conduct at site or any family link with study site staff * Pregnant, parturient or lactating women, as per Public Health Code (CSP)(Article L-1121-5) * Persons deprived of their liberty by a judicial or administrative decision, and those admitted to a health or social facility, as per CSP (Article L-1121-6) * Persons covered by a measure of legal protection or unable to provide a written, dated and signed informed consent, as per CSP(Article L-1121-8) * Patient without Social Security Insurance